https://www.yiliao.com/index.php?action=history&feed=atom&title=%E5%85%8D%E7%96%AB%E6%B2%BB%E7%96%97%E5%9F%BA%E5%9B%A0%E9%BB%91%E5%90%8D%E5%8D%95
免疫治疗基因黑名单 - 版本历史
2026-06-03T01:55:48Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E5%85%8D%E7%96%AB%E6%B2%BB%E7%96%97%E5%9F%BA%E5%9B%A0%E9%BB%91%E5%90%8D%E5%8D%95&diff=312306&oldid=prev
2026年1月1日 (四) 22:09 77921020
2026-01-01T22:09:40Z
<p></p>
<a href="https://www.yiliao.com/index.php?title=%E5%85%8D%E7%96%AB%E6%B2%BB%E7%96%97%E5%9F%BA%E5%9B%A0%E9%BB%91%E5%90%8D%E5%8D%95&diff=312306&oldid=312302">显示更改</a>
77921020
https://www.yiliao.com/index.php?title=%E5%85%8D%E7%96%AB%E6%B2%BB%E7%96%97%E5%9F%BA%E5%9B%A0%E9%BB%91%E5%90%8D%E5%8D%95&diff=312302&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-01T21:48:18Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 25px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 15px;"><br />
<h2 style="margin: 0; color: #b91c1c; font-size: 1.4em; display: flex; align-items: center;"><br />
<span style="display: inline-block; width: 8px; height: 24px; background-color: #b91c1c; margin-right: 12px; border-radius: 2px;"></span><br />
免疫治疗“黑名单”基因 (ICI Blacklist)<br />
</h2><br />
<p style="font-size: 0.95em; color: #64748b; margin-top: 8px;"><br />
以下基因变异通常提示患者对 PD-1/PD-L1 抑制剂<strong>[[原发性耐药]]</strong>，甚至存在<strong>[[超进展]]</strong> (HPD) 风险。检出此类变异时，免疫单药治疗需极度谨慎。<br />
</p><br />
</div><br />
<br />
<div style="background-color: #fff1f2; border: 1px solid #fda4af; border-radius: 8px; padding: 15px 20px; margin-bottom: 20px;"><br />
<div style="font-weight: bold; color: #9f1239; font-size: 1.1em; margin-bottom: 8px;"><br />
⚠️ 风险等级：高 (超进展 HPD)<br />
</div><br />
<div style="margin-bottom: 10px;"><br />
<strong>涉及基因：</strong> <strong>[[MDM2]]</strong> (扩增), <strong>[[MDM4]]</strong> (扩增), <strong>[[EGFR]]</strong> (特定突变)<br />
</div><br />
<div style="font-size: 0.95em; color: #334155; background: rgba(255,255,255,0.6); padding: 10px; border-radius: 6px;"><br />
<strong>机制简述：</strong> <br />
<br>MDM2/4 扩增导致 <strong>[[p53]]</strong> 功能完全丧失，T细胞分泌的 <strong>[[IFN-γ]]</strong> 无法启动凋亡，反而通过旁路激活 <strong>[[JAK-STAT]]</strong> 等生长通路，导致肿瘤被免疫药物“催熟”疯长。<br />
</div><br />
</div><br />
<br />
<div style="background-color: #f0f9ff; border: 1px solid #bae6fd; border-radius: 8px; padding: 15px 20px; margin-bottom: 20px;"><br />
<div style="font-weight: bold; color: #0369a1; font-size: 1.1em; margin-bottom: 8px;"><br />
❄️ 风险等级：中 (原发耐药 / 冷肿瘤)<br />
</div><br />
<div style="margin-bottom: 10px;"><br />
<strong>涉及基因：</strong> <strong>[[STK11]]</strong> (LKB1), <strong>[[KEAP1]]</strong>, <strong>[[PTEN]]</strong> (缺失)<br />
</div><br />
<div style="font-size: 0.95em; color: #334155; background: rgba(255,255,255,0.6); padding: 10px; border-radius: 6px;"><br />
<strong>机制简述：</strong> <br />
<br>尤其是 <strong>STK11/KEAP1</strong> 共突变的肺腺癌，表现为典型的<strong>[[免疫沙漠型]]</strong>微环境。缺乏 CD8+ T 细胞浸润，无论 PD-L1 表达高低，免疫治疗有效率极低（ORR < 10%）。<br />
</div><br />
</div><br />
<br />
<div style="background-color: #fefce8; border: 1px solid #fde047; border-radius: 8px; padding: 15px 20px; margin-bottom: 20px;"><br />
<div style="font-weight: bold; color: #854d0e; font-size: 1.1em; margin-bottom: 8px;"><br />
🛡️ 风险等级：中 (获得性/原发耐药)<br />
</div><br />
<div style="margin-bottom: 10px;"><br />
<strong>涉及基因：</strong> <strong>[[JAK1]]</strong> / <strong>[[JAK2]]</strong> (失活突变), <strong>[[B2M]]</strong> (缺失)<br />
</div><br />
<div style="font-size: 0.95em; color: #334155; background: rgba(255,255,255,0.6); padding: 10px; border-radius: 6px;"><br />
<strong>机制简述：</strong> <br />
<br><strong>JAK1/2 缺失</strong>导致肿瘤细胞对 IFN-γ 不敏感，无法上调 PD-L1 或 MHC 分子；<strong>B2M 缺失</strong>导致 MHC-I 类分子无法呈递抗原，使肿瘤细胞对 T 细胞“隐身”。<br />
</div><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 40px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">权威参考文献 (Key References)</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Kato S, et al. (2017).</strong> <em>Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.</em> <strong>[[Clinical Cancer Research]]</strong>. 23(15):4242-4250.<br><br />
<span style="color: #475569;">[核心发现]：定义了“超进展”，并首次确认 MDM2/MDM4 扩增及 EGFR 突变是 HPD 的特异性基因组标志物。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Skoulidis F, et al. (2018).</strong> <em>STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.</em> <strong>[[Cancer Discovery]]</strong>. 8(7):822-835.<br><br />
<span style="color: #475569;">[核心发现]：确立了 STK11/KEAP1 突变是 KRAS 突变肺癌中对 PD-1 抑制剂产生原发性耐药的主要驱动因素，定义了“冷肿瘤”亚型。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Zaretsky JM, et al. (2016).</strong> <em>Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.</em> <strong>[[New England Journal of Medicine]] (NEJM)</strong>. 375(9):819-829.<br><br />
<span style="color: #475569;">[核心发现]：通过对比治疗前后的活检样本，首次发现 JAK1/2 和 B2M 的失活突变是导致 PD-1 抑制剂获得性耐药的直接机制。</span><br />
</p><br />
</div><br />
<br />
</div></div>
77921020